LCA10 trial of CRISPR genome editing treatment initiated
A phase 1/2 clinical trial of AGN-151587, an experimental CRISPR-based genome editing medicine for the treatment of Leber congenital amaurosis 10, has been initiated by Allergan and Editas Medicine, according to a press release.
The open label Brilliance trial will evaluate the safety, tolerability and efficacy of AGN-151587 (EDIT-101) in approximately 18 patients in up to five cohorts across three dose levels, the release said.
Patients will receive a single subretinal injection in one eye following vitrectomy.
“Beginning patient enrollment in the AGN-151587 clinical trial with our partners at Editas is an important step toward our goal of developing a game-changing, transformative, CRISPR-based medicine for people with LCA10,” David Nicholson, PhD, chief research and development officer at Allergan, said in the release.